Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Intravenously administered tissue plasminogen activator (IV-tPA) remains the only approved drug therapy for achieving arterial recanalization in patients with acute ischemic stroke (AIS). However, numerous contraindications need to be carefully excluded before initiating the thrombolytic therapy. Some of these contraindications are based on expert opinions and not founded in good science.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi